Prostamax
- Category
- Bioregulators
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic tetrapeptide marketed for prostate health, promoted to calm chronic inflammation and support tissue repair as the prostate ages. The case is speculative, resting on mechanistic and animal-model reasoning rather than controlled human trials, with no established human safety profile. A theoretical concern about promoting growth in existing prostate malignancy is unresolved. Products sold online are unregulated, and it is not an approved drug in the US.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Prostamax is a synthetic four-amino-acid peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology, derived from bovine prostate tissue. It is designed to support prostate gland health by reducing chronic inflammation, preventing tissue scarring (fibrosis), and promoting cellular repair. With aging, the prostate commonly develops chronic inflammation and structural changes that can lead to benign enlargement and other issues. Prostamax is not available as a pharmaceutical or dietary supplement.
How it works in the body
A tetrapeptide bioregulator that targets prostate epithelial and stromal cells. It modulates gene expression related to prostate cell proliferation, inflammatory cytokine production, and the balance between cell growth and apoptosis in prostate tissue.
Research overview
Prostamax works at the level of gene regulation by entering cells and loosening tightly packed DNA (heterochromatin) that becomes silenced during aging. By 'unpacking' these regions, it reactivates genes involved in tissue repair and reduces inflammatory processes. Studies in cells from elderly donors (ages 75-88) showed the peptide doubled chromosomal exchange activity and tripled the activity of genes producing ribosomal RNA — indicators of rejuvenated cellular function. In the most substantial animal study, Prostamax was tested in 60 rats with chronic prostatitis and outperformed saw palmetto extract and animal prostate extracts in reducing inflammation and preventing tissue scarring. In tissue culture experiments, it stimulated prostate repair at extremely low concentrations (0.05 nanograms per milliliter). However, no controlled peer-reviewed human trials were identified (patents describe human use), all studies come from a single research group, and no independent replication has been published.
Who researches Prostamax?
Commonly researched by
People exploring hormone and sexual health
Researched for effects on hormone levels, sexual function, or fertility.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(5)
Rated by level of concern
Very limited human evidence — safety and efficacy remain unestablished
HighPubMed "prostamax": 6 records (PMIDs 15612551, 19359734, 15085253, 23221144, 17152728, 28948547); no ClinicalTrials.gov registration identified
Theoretical risk of tumor promotion in active prostate malignancy
TheoreticalPMID 17152728 (explant growth stimulation); PMID 23221144 (SCE 5.9 to 12.0 per cell)
Unregulated product quality (research-grade sources)
HighNo FDA approval or DailyMed listing for Prostamax / Lys-Glu-Asp-Pro
Limited safety data and lack of independent validation
HighPMIDs 15612551, 19359734, 23221144, 17152728 — a single research lineage (shared author lists)
Allergic reaction or peptide hypersensitivity
LowNo reported hypersensitivity cases in the Prostamax literature; general peptide-class reasoning
Interaction summary(7)
Rated by direction with this peptide
Androgen deprivation therapy / GnRH agonists (leuprolide, degarelix) and antiandrogens
CautionTheoreticalProstamax stimulated prostate explant outgrowth in rat organotypic culture, so a trophic prostate signal runs directly counter to the therapeutic goal of androgen deprivation; no interaction study exists in any species, but the direction of concern is clear.
PMID 17152728 (mechanistic basis only; no interaction study published)
Cadmium and other heavy-metal exposure
CautionTheoreticalThe one study that combined Prostamax with other agents included Cd(II), which independently decondenses and partially denatures heterochromatin — the same direction as KEDP. The published abstract reports each agent's effect separately and does not report a measured combined outcome, so additive chromatin destabilization is inference from co-directionality, not an observed result.
PMID 19359734
Copper (Cu II) supplementation
NeutralTheoreticalCu(II) additionally condenses heterochromatin, the opposite of Prostamax's reported decondensing effect, so the two might partially offset in vitro; this is inferred from separate single-agent results, as the published abstract reports no combined measurement. No clinical inference is warranted.
PMID 19359734
5-alpha-reductase inhibitors (finasteride, dutasteride)
NeutralTheoreticalNo shared pathway, no metabolic overlap, and no reported interaction — Prostamax would not be expected to alter finasteride pharmacology, though it also has no evidence of adding benefit in BPH.
No published interaction data; mechanism-based reasoning
Alpha-1 blockers (tamsulosin, alfuzosin, silodosin)
NeutralTheoreticalAlpha-blockers act on smooth-muscle adrenoceptors with no plausible intersection with a nuclear/chromatin-level peptide effect; no interaction has been reported or studied.
No published interaction data; mechanism-based reasoning
Antibiotics for bacterial prostatitis (fluoroquinolones, trimethoprim-sulfamethoxazole)
CautionLowNo pharmacological interaction is expected; the hazard is substitution rather than interaction — Prostamax has no antimicrobial evidence of any kind and must not displace or delay guideline antibiotic therapy for culture-positive prostatitis, where delay carries real clinical consequences.
No published interaction data; clinical-practice consideration
Testosterone replacement therapy
CautionTheoreticalCombining an androgenic growth stimulus with a peptide that stimulated prostate explant growth is a theoretical compounding of prostatic proliferative drive; entirely unstudied, and PSA monitoring practice for TRT should not be relaxed.
PMID 17152728 (mechanistic basis only; no combination study exists)
Known risks(5)
Very limited human evidence — safety and efficacy remain unestablished
HighUnlike many other Khavinson bioregulators, Prostamax (as the defined KEDP tetrapeptide) has no controlled peer-reviewed human trials. Human use is described in patents, but independently validated human safety and efficacy remain unestablished. The peer-reviewed studies cited here are preclinical or ex vivo. Its pharmacokinetics, bioavailability, effective dosing, and potential adverse effects in humans remain uncharacterized.
Theoretical risk of tumor promotion in active prostate malignancy
High (specific population)Prostamax promotes gene reactivation, chromatin decondensation, and cellular proliferative activity. In the presence of an active prostate malignancy, this mechanism could theoretically promote tumor growth by stimulating protein synthesis and cell proliferation in malignant cells. This risk has not been studied, but the Khavinson peptide literature notes that peptide bioregulators are not recommended when active malignancy exists. Men with prostate cancer or suspected prostate cancer should not use Prostamax without oncologist consultation.
Unregulated product quality (research-grade sources)
ModerateUnregulated Prostamax products sold online are not manufactured under pharmaceutical GMP standards and is not subject to FDA quality oversight. Purity, identity, sterility, and endotoxin levels may vary among unregulated products sold online. Contamination with lipopolysaccharides or other impurities, or incorrect peptide sequences, are potential concerns. Poor manufacturing practices can cause adverse reactions unrelated to the peptide itself.
Limited safety data and lack of independent validation
ModerateAll preclinical safety data originates from a single research group (Khavinson and collaborators) with small sample sizes. No independent safety monitoring, pharmacovigilance, or large-scale safety studies have been conducted. Animal toxicology is described in a patent; independent peer-reviewed toxicology remains unverified. The absence of reported adverse events in published studies may reflect limited study scope rather than true safety.
Allergic reaction or peptide hypersensitivity
LowAs with any injectable peptide, allergic reactions are possible. Individuals with known hypersensitivity to peptides or any component of the product should exercise caution. Mild injection-site reactions (redness, swelling, tenderness) have been reported anecdotally and are typical for subcutaneous or intramuscular peptide injections.
Drug interactions(6)
Alpha-1 adrenergic blockers (tamsulosin, alfuzosin, doxazosin)
These are first-line medications for BPH and lower urinary tract symptoms. Prostamax has not been studied in combination with alpha-blockers. The related compound Prostatilen has been used alongside tamsulosin in clinical practice (Kuzmin et al. 2022). No adverse interaction is expected based on different mechanisms of action, but formal interaction data do not exist.
5-alpha reductase inhibitors (finasteride, dutasteride)
5-ARIs reduce prostate size by blocking testosterone-to-DHT conversion. Prostamax acts via epigenetic chromatin remodeling and anti-inflammatory mechanisms, a completely different pathway. Theoretical complementary effects are possible, but no interaction studies have been conducted. Caution warranted as both agents affect prostate tissue biology.
NSAIDs and anti-inflammatory medications
The Borovskaya et al. 2013 study suggested Prostamax's anti-inflammatory effects in the prostate may exceed those of conventional anti-inflammatory approaches. No interaction is expected, but the Kuzmin et al. 2022 study with Uroprost-D (a related prostatic peptide product) showed it was a 'pathogenetically reasonable alternative to NSAIDs' rather than an add-on. Potential additive anti-inflammatory effects have not been studied.
Other Khavinson peptide bioregulators (Epitalon, Thymalin, Testagen, Crystagen)
Prostamax targets prostate tissue, while Epitalon targets pineal/telomeres, Thymalin targets thymus/immunity, and Testagen targets male reproductive function. No adverse interactions have been reported. The Crystagen tripeptide (EDP) shares two amino acids with Prostamax (KEDP) but targets different tissue. Formal interaction studies have not been conducted.
Immunosuppressants
Prostamax has demonstrated immunomodulatory effects including altered lymphocyte chromatin structure and enhanced ribosomal gene activity. Theoretical interaction with immunosuppressive therapy has not been studied. Caution is warranted in transplant patients or those on immunosuppressive regimens.
Anticoagulants and antiplatelet agents
No interaction data exist. Prostamax's mechanism of action (chromatin remodeling, anti-inflammatory) does not suggest a direct interaction with coagulation pathways. However, the absence of pharmacokinetic data means unexpected interactions cannot be ruled out.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 6
The peer-reviewed evidence described here is mainly preclinical and ex vivo. Patent RU2177802C1 additionally reports human KEDP treatment series and animal toxicology; these disclosures are not independently validated clinical trials. The cited rat and cell studies do not establish human efficacy or safety. No controlled peer-reviewed human trial was identified. The most substantive evidence comes from the Borovskaya et al. 2013 study in 60 rats, which demonstrated anti-inflammatory, anti-fibrotic, and anti-atrophic effects superior to established comparator agents. Ex vivo studies in human lymphocytes from elderly subjects (Khavinson et al. 2004, Dzhokhadze et al. 2012) show measurable epigenetic effects on chromatin structure. The organotypic tissue culture study (Zakutskii et al. 2006) confirms tissue-specific activity on prostate explants. The major limitations are origin in a single research group, small sample sizes, no peer-reviewed pharmacokinetic or toxicology data, and no independent replication by non-affiliated laboratories.
Researched for(6)
Rated by confidence in the evidence
Reduction of chronic prostate inflammation
SpeculativeA rat prostatitis study reports reduced inflammation; human benefit remains unestablished.
Borovskaya et al. 2013, DOI 10.4236/mri.2013.23007: synthetic Prostamax in rat prostatitis.
Prevention of sclerotic and atrophic processes in prostate tissue
SpeculativeA rat prostatitis study measured sclerosis and atrophy; human prevention remains unestablished.
Borovskaya et al. 2013, DOI 10.4236/mri.2013.23007: rat prostate histology.
Epigenetic reactivation of age-silenced genes via chromatin decondensation
LowHuman lymphocyte study found chromatin decondensation signals, but unreplicated and not clinical.
PMID 23221144 (SCE 5.9±0.2 to 12.0±0.28 per cell; Ag-NOR 0.95 to 2.5 per cell); corroborating same-lineage work that directly included Prostamax: PMID 15085253; same-lineage work on related peptides: PMID 12533768 (Livagen), PMID 14647006 (Epitalon)
Stimulation of reparative processes in prostate tissue during aging
SpeculativeSingle rat explant study showed tissue growth, a proliferation proxy, not confirmed repair.
PMID 17152728
Enhancement of sexual function in chronic prostatitis
SpeculativeA Prostamax rat study reports increased sexual activity; clinical benefit remains unestablished.
Borovskaya et al. 2013, DOI 10.4236/mri.2013.23007: Prostamax animal study.
Modification of chromatin thermal stability (structural remodeling)
LowHuman cell studies measured chromatin thermal shifts, but only in vitro with no health outcome.
PMID 15612551; PMID 19359734
Benefits(6)
Reduction of chronic prostate inflammation
Borovskaya et al. 2013 (Modern Research in Inflammation, DOI 10.4236/mri.2013.23007) — In 60 Wistar rats with surgically induced chronic aseptic prostatitis, 15 days of intramuscular Prostamax (20 mcg/kg/day) significantly reduced the intensity of chronic inflammation including swelling, vascular hyperemia, and lymphoid infiltration. Prostamax decreased collagen fiber area 2.5-fold versus untreated controls and preserved epithelial structures, demonstrating both anti-inflammatory and anti-fibrotic effects.
Prevention of sclerotic and atrophic processes in prostate tissue
Borovskaya et al. 2013 — Prostamax prevented the development of sclerotic and atrophic processes in the prostate gland, distinguishing it from comparator agents (Samprost/Prostatilen and Prostamol Uno/Serenoa repens extract at 50 mg/kg) which only inhibited sclerosis without preventing atrophy. The authors concluded that Prostamax's efficiency surpasses that of widespread prostatotropic agents.
Epigenetic reactivation of age-silenced genes via chromatin decondensation
Khavinson, Lezhava & Malinin 2004 (Bulletin of Experimental Biology and Medicine, PMID 15085253) — Prostamax induced activation of ribosome genes, decondensation of densely packed chromatin fibrils, and release of genes repressed by age-specific condensation of euchromatin regions in leukocytes from subjects aged 75-88 years. Specifically caused decondensation of chromosome 1 pericentromeric structural heterochromatin. Dzhokhadze et al. 2012 (Georgian Medical News, PMID 23221144) — Prostamax increased SCE frequency to 12.0 +/- 0.28 per cell (from 5.9 +/- 0.2 in controls) and increased Ag-positive NORs to 2.5 per cell (from 0.95 in controls), while reducing large segments of pericentromeric heterochromatin.
Stimulation of reparative processes in prostate tissue during aging
Zakutskii et al. 2006 (Advances in Gerontology, PMID 17152728) — In organotypic tissue cultures of prostate gland explants from young (3-week-old) and aged (18-month-old) rats, Prostamax at 0.05 ng/mL showed a tissue-specific stimulating effect on prostatic tissue compared to controls. The authors concluded that bioregulatory peptides including Prostamax can be used for stimulation of reparative processes in appropriate tissues during aging.
Enhancement of sexual function in chronic prostatitis
Borovskaya et al. 2013 — In addition to histological improvements, Prostamax intensified sexual activity in rats with chronic aseptic prostatitis, offering functional benefits beyond tissue-level anti-inflammatory effects.
Modification of chromatin thermal stability (structural remodeling)
Meskhi et al. 2004 (Biofizika, PMID 15612551) — Microcalorimetric analysis of human lymphocyte chromatin showed that Prostamax caused redistribution of heat among endotherms and shifted denaturation peaks to lower temperatures by 2.9 and 1.0 degrees C respectively, indicating partial relaxation of the 30-nm chromatin fiber into 10-nm filaments. This represents a measurable biophysical effect on nucleosomal organization.
Key studies(6)
Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications
Experimental animal study (rat)60 male Wistar rats (330-500 g, 4 months old); 20 control, 10 baseline, 30 treatment15 days treatment (starting day 30 post-surgery); evaluation at day 45Borovskaya TG, Pakhomova AV, Vychuzhanina AV, Poluektova ME, Fomina TI, Ermolaeva LA, Schemerova JA, Granstrem OK, Neplochov EA
Modern Research in Inflammation
2013
Prostamax (20 mcg/kg intramuscularly for 15 days) reduced the intensity of chronic inflammation (swelling, hyperemia, lymphoid infiltration), prevented development of sclerotic and atrophic processes in the prostate gland, decreased collagen fiber area 2.5-fold versus control, and preserved epithelial structures. Its efficiency surpassed that of Samprost (20 mcg/kg IM) and Prostamol Uno (50 mg/kg intragastrically), which only inhibited sclerosis without preventing atrophy. Also intensified sexual activity in treated animals.
Effects of short peptides on lymphocyte chromatin in senile subjects
Ex vivo experimental study (human lymphocytes)Leukocytes from elderly subjects aged 75-88 yearsCell culture experimentKhavinson VKh, Lezhava TA, Malinin VV
Bulletin of Experimental Biology and Medicine
2004
All tested peptides (Vilon, Epithalon, Livagen, Prostamax, and Cortagen) induced activation of ribosome genes, decondensation of densely packed chromatin fibrils, and release of genes repressed by age-specific condensation (deheterochromatinization of facultative chromatin). Prostamax specifically led to decondensation of chromosome 1 pericentromeric structural heterochromatin. The results demonstrate that short peptides activate heterochromatin and heterochromatinized regions of chromosomes in senile subjects.
Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)
Ex vivo experimental study (human lymphocytes)Cultured cells from elderly individuals aged 75-86 yearsCell culture experimentDzhokhadze TA, Buadze TZh, Gaiozishvili MN, Baratashvili NA, Lezhava TA
Georgian Medical News
2012
Prostamax (KEDP) significantly altered chromosomal parameters in cells from elderly donors: increased sister chromatid exchange frequency to 12.0 +/- 0.28 per cell (versus 5.9 +/- 0.2 in untreated controls), increased Ag-positive nucleolar organizer regions to 2.5 per cell (versus 0.95 in controls), and reduced large segments of C-pericentromeric heterochromatin for chromosomes 1 and 9. Demonstrated the peptide's ability to induce decondensation and deheterochromatinization of chromatin during aging.
The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ
Ex vivo biophysical study (human lymphocytes)Human lymphocyte chromatin samplesMicrocalorimetric analysisMeskhi T, Khachidze D, Barbakadze Sh, Madzhagaladze G, Gorgoshidze M, Monaselidze D, Lezhava T, Tadumadze N
Biofizika
2004
Microcalorimetric analysis demonstrated that Prostamax caused redistribution of heat among chromatin endotherms and shifted denaturation peaks to lower temperatures by 2.9 and 1.0 degrees C respectively. The changes were attributed to partial relaxation of the 30-nm-thick chromatin fiber into the 10-nm filament, indicating modest structural modifications in nucleosomal organization without dramatic alterations to overall chromatin architecture.
The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
Ex vivo experimental study (organotypic tissue culture)Prostate gland explants from young (3-week-old) and aged (18-month-old) ratsTissue culture experimentZakutskii AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN
Advances in Gerontology
2006
Synthetic peptides cardiogen, bronchogen, prostamax, and pancragen were tested in organotypic tissue cultures of their target organs (heart, lungs, prostate, pancreas). Prostamax at 0.05 ng/mL showed a tissue-specific stimulating effect on prostatic gland cultures compared to controls in all age groups. The authors concluded these bioregulatory peptides can stimulate reparative processes in appropriate tissues during aging.
Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan
Comparative bioinformatics / experimental studyProtein sequence analysis across speciesNot applicable (sequence analysis)Khavinson VKh, Kormilets DYu, Mar'yanovich AT
Bulletin of Experimental Biology and Medicine
2017
Discovered that motifs of short-chain epigenetically active peptides (including KEDP-related sequences) are present in proteins of the long-lived African naked mole rat (Heterocephalus glaber), located between lysine and arginine residues facilitating release via limited proteolysis. Some of these epigenetic regulators are absent from proteins of short-lived species (Rattus norvegicus, Mus musculus), suggesting an evolutionary role for these peptides in longevity.
Regulation & availability
Why researchers look at it
In a controlled study of 60 rats with chronic prostatitis, Prostamax outperformed both saw palmetto and animal prostate extracts in reducing inflammation and preventing scarring, while ex vivo studies in cells from elderly donors (ages 75-88) showed doubled chromosomal exchange and tripled ribosomal gene expression. No controlled peer-reviewed human trials were identified; patents describe human use. If future human studies confirm these findings, Prostamax could offer targeted prostate tissue maintenance beyond symptom management.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- Not FDA-approved. FDA identified a marketed Prostamax product as an unapproved new drug in a June 17, 2026 warning letter. No FDA-approved product or indication was identified. An IND filing was not publicly verified; public silence cannot establish that none exists. No lawful bulk-compounding pathway was established from the FDA lists reviewed. No human pharmacokinetic data have been published.
- WADA status
- Prostamax is not individually named on the WADA 2026 Prohibited List. S0 prohibits otherwise-unlisted pharmacological substances without governmental approval for human therapeutic use at all times, including outside competition. No qualifying therapeutic approval was verified for Prostamax. Athletes should obtain a product-specific assessment from their anti-doping organization.
- Prescribability
- No FDA-approved Prostamax prescription product or qualifying US bulk-compounding basis was verified. A physician's prescription alone does not establish eligibility under sections 503A or 503B.
- Availability
- Prostamax (as the defined KEDP tetrapeptide) is not available through US or EU pharmacies, is not listed in any pharmacopeia, and cannot be obtained through standard prescription channels. The related Russian pharmaceutical Prostatilen (Samprost), the polypeptide prostatic extract from which Prostamax was derived, is approved in Russia as rectal suppositories and injection solution. Prostatilen contains a complex mixture of short peptides from bovine prostate tissue, of which Prostamax (KEDP) is thought to be one active component. Some functional medicine and bioregulator-focused practitioners at international longevity clinics use Prostamax in anti-aging protocols.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(13)
- 1971Vladimir Khavinson begins research on peptide bioregulators as part of a Soviet military research program at the Military Medical Academy in Leningrad (St. Petersburg).
- 1980sProstatic peptide complex (Prostatilen/Samprost) is first obtained from bovine prostate tissue by ultrafiltration. Prostatilen becomes an approved pharmaceutical in Russia for chronic prostatitis and BPH.
- 1992St. Petersburg Institute of Bioregulation and Gerontology is established as Khavinson's primary research center for peptide bioregulator development.
- 2000sProstamax tetrapeptide (Lys-Glu-Asp-Pro) is identified and synthesized as a defined active sequence from bovine prostate tissue extracts at the St. Petersburg Institute.
- 2002Khavinson publishes comprehensive 133-page review 'Peptides and Ageing' describing clinical trials of prostate peptide preparations among other bioregulators (PMID 12374906).
- 2004Khavinson, Lezhava & Malinin publish first study directly testing Prostamax on human lymphocyte chromatin in elderly subjects, demonstrating heterochromatin decondensation (PMID 15085253). Meskhi et al. publish microcalorimetric study of Prostamax effects on chromatin thermal stability (PMID 15612551).
- 2006Zakutskii et al. publish organotypic tissue culture study showing Prostamax tissue-specific stimulatory effects on prostate gland explants from young and aged rats (PMID 17152728).
- 2012Dzhokhadze et al. publish detailed study quantifying Prostamax-induced deheterochromatinization in cells from elderly donors, showing doubled SCE frequency and tripled NOR activity (PMID 23221144).
- 2013Borovskaya et al. publish the most substantive preclinical study in 60 rats with chronic aseptic prostatitis, demonstrating Prostamax superiority over Serenoa repens and animal prostate extracts (DOI 10.4236/mri.2013.23007).
- 2017Khavinson et al. publish evolutionary analysis finding KEDP-related peptide motifs in proteins of long-lived naked mole rats but absent in short-lived rodent species (PMID 28948547).
- 2020sGains attention in Western longevity and biohacking communities as part of the Khavinson bioregulator protocol.
- 2022Kuzmin et al. publish human clinical study of Uroprost-D (a related prostatic peptide bioregulator formulation with DMSO) in 47 men with chronic abacterial prostatitis, showing superiority over NSAIDs at 60-day follow-up (DOI 10.17816/uroved111581).
- 2026-03Prostamax has no identified FDA approval. An IND filing has not been publicly verified; FDA generally does not disclose an IND's existence unless it has already been publicly acknowledged. No clinical trials are registered on ClinicalTrials.gov. Not approved as a pharmaceutical or dietary supplement in any jurisdiction.
Sources & FAQs
Research sources(11)
- Borovskaya et al. 2013 — Prostamax efficiency in chronic aseptic prostatitis (rat model)
- Khavinson, Lezhava & Malinin 2004 — Short peptides on lymphocyte chromatin in senile subjects
- Dzhokhadze et al. 2012 — Deheterochromatinization by KEDP in old age
- Meskhi et al. 2004 — Prostamax influence on heterochromatin of human lymphocytes
- Zakutskii et al. 2006 — Tissue-specific effect of synthetic peptides in organotypic culture
- Khavinson, Kormilets & Mar'yanovich 2017 — Peptides as epigenetic regulators and lifespan
- Khavinson 2002 — Peptides and Ageing (comprehensive review, 133 pages)
- Khavinson & Anisimov 2009 — Peptide regulation of aging: 35-year research experience
- Khavinson et al. 2013 — Peptide bioregulators: new class of geroprotectors (clinical review)
- Kuzmin, Slesarevskaya & Al-Shukri 2022 — Bioregulatory therapy for chronic abacterial prostatitis
- WADA 2026 Prohibited List
Frequently asked questions(5)
What is the difference between Prostamax and Prostatilen (Samprost)?
Prostatilen (brand name of Samprost) is a polypeptide complex extracted from bovine prostate tissue that has been an approved pharmaceutical in Russia since 1992, available as rectal suppositories and injections. It contains a mixture of short peptides. Prostamax is a single defined synthetic tetrapeptide (Lys-Glu-Asp-Pro, KEDP) that was identified as one of the active sequences from the natural prostatic extract. Prostamax is the more refined, standardized version with a defined molecular composition, while Prostatilen is a crude tissue extract. In Khavinson's classification system, Samprost is a 'Cytomaxes' (natural extract) and Prostamax is a 'Cytogens' (synthesized peptide). Prostatilen has clinical data from human studies (37 patients with chronic prostatitis and 15 with prostatic adenoma), while Prostamax's cited peer-reviewed evidence is preclinical; patents also describe human KEDP use.
Is Prostamax safe? Are there side effects?
Published preclinical studies report a favorable tolerability profile, with no significant toxic effects observed in animal models. Patents describe human use and animal toxicology, but independently validated human safety remains unestablished. A critical contraindication is active prostate malignancy: Khavinson-class peptides stimulate protein synthesis and gene expression, which could theoretically promote tumor growth, though this has not been studied. Another contraindication is known peptide hypersensitivity. Published safety data are limited to small preclinical studies from a single research group.
Can Prostamax treat benign prostatic hyperplasia (BPH) or prostatitis?
Prostamax has shown anti-inflammatory and anti-fibrotic effects in a rat model of chronic aseptic prostatitis, outperforming Serenoa repens extract and animal prostate extracts (Borovskaya et al. 2013). Patents describe human use for prostate conditions; controlled peer-reviewed efficacy trials were not identified. The related compound Prostatilen has human clinical data showing symptom improvement in chronic prostatitis and prostatic adenoma. Prostamax should not be used as a substitute for established BPH or prostatitis medications without medical supervision.
How does Prostamax work at the molecular level?
Prostamax functions as an epigenetic regulator that alters chromatin structure. It promotes the decondensation of heterochromatin — tightly packed, transcriptionally silent DNA-protein complexes that accumulate during aging. This involves relaxation of the 30-nm chromatin fiber into 10-nm filaments, increasing sister chromatid exchange frequency, activating nucleolar organizer regions (which control ribosomal RNA production), and reducing pericentromeric heterochromatin. The net effect is reactivation of genes that were silenced by age-related chromatin condensation, enabling cells to resume reparative and biosynthetic activities associated with younger tissue states.
Is the research on Prostamax credible?
The research is published in legitimate peer-reviewed journals (Bulletin of Experimental Biology and Medicine, Advances in Gerontology, Georgian Medical News, Biofizika, Modern Research in Inflammation) that are indexed in PubMed. However, all published studies originate from Khavinson-affiliated research groups, sample sizes are small, and no independent replication has been published by Western or international research groups. No controlled peer-reviewed human trials were identified; patents describe human use. The rat prostatitis study (Borovskaya et al. 2013) provides the strongest preclinical evidence with a proper control group and multiple comparators. The chromatin studies (Khavinson et al. 2004, Dzhokhadze et al. 2012, Meskhi et al. 2004) provide consistent mechanistic data. Independent validation would significantly strengthen the evidence base.